# Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Source: https://onco.cc/trials/nct07480213/  
OnCo record `nct07480213` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EB-DART-NK01 (DLL3/CD56 CAR-NK cells) in small-cell lung cancer, run by Beijing Biotech, now recruiting.

## Summary

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) is a phase 1/2 interventional study registered as NCT07480213 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: EB-DART-NK01 (DLL3/CD56 CAR-NK cells) and Lymphodepleting chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07480213
- Phase: 1/2
- Setting: A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
- Sponsor: Beijing Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07480213: https://clinicaltrials.gov/study/NCT07480213

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07480213.json